📊 OVID Key Takeaways
Is Ovid Therapeutics Inc. (OVID) a Good Investment?
Ovid is facing a critical cash runway crisis with only ~4 months of liquidity at current burn rates (-$38.3M quarterly operating cash flow) against modest cash reserves ($13.2M), necessitating imminent dilutive capital raise. Despite impressive 1181% revenue growth, the company's operating margin of -585% indicates costs vastly exceed commercial traction, with no clear path to profitability or cash flow breakeven in the foreseeable future. Early-stage pharmaceutical operations require sustained funding; current financials suggest high distress risk and shareholder dilution.
Why Buy Ovid Therapeutics Inc. Stock? OVID Key Strengths
- Revenue achieved 1181% YoY growth, indicating potential commercialization milestone or drug approval
- Zero debt with $130.7M stockholders equity provides capital structure flexibility for raises
- Exceptional liquidity (8.97x current ratio) offers near-term operational cushion
- Net income loss improving 34.1% YoY suggests operational leverage potential
- Recent insider activity (12 Form 4 filings in 90 days) indicates management confidence
OVID Stock Risks: Ovid Therapeutics Inc. Investment Risks
- Critical liquidity crisis: $13.2M cash against -$38.3M quarterly operating burn implies 4-month runway requiring imminent capital raise
- Unsustainable profitability: -585% operating margin indicates operating expenses are nearly 6x revenue; commercialization traction insufficient to support cost structure
- Early revenue base of $7.3M too small to validate commercial viability; insufficient to cover operating costs or achieve scale
- Capital raise necessity will create significant shareholder dilution and potential stock price pressure
- Biotech binary risk: early-stage pharmaceutical company dependent on single or limited drug portfolio; regulatory or market setbacks could accelerate distress
Key Metrics to Watch
- Quarterly revenue growth rate and trajectory toward cost coverage; cash burn sustainability
- Operating cash flow trend and path to positive cash generation or breakeven runway
- Capital raise announcements, terms, and implied dilution impact on existing shareholders
- Operating expense ratio and evidence of cost reduction or operational restructuring
- Cash balance relative to quarterly burn rate; timing of capital requirement materialization
Ovid Therapeutics Inc. (OVID) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.97x current ratio provides a solid financial cushion.
OVID Profit Margin, ROE & Profitability Analysis
OVID vs Healthcare Sector: How Ovid Therapeutics Inc. Compares
How Ovid Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ovid Therapeutics Inc. Stock Overvalued? OVID Valuation Analysis 2026
Based on fundamental analysis, Ovid Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ovid Therapeutics Inc. Balance Sheet: OVID Debt, Cash & Liquidity
OVID Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ovid Therapeutics Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.77 indicates the company is currently unprofitable.
OVID Revenue Growth, EPS Growth & YoY Performance
OVID Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $132.0K | -$4.7M | N/A |
| Q2 2025 | $169.0K | -$3.2M | N/A |
| Q1 2025 | $130.0K | -$10.2M | N/A |
| Q3 2024 | $109.0K | $8.5M | $-0.16 |
| Q2 2024 | $75.0K | -$3.2M | $-0.04 |
| Q1 2024 | $66.0K | -$11.7M | $-0.17 |
| Q3 2023 | $11.1K | -$11.3M | $-0.16 |
| Q2 2023 | N/A | -$12.4M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ovid Therapeutics Inc. Dividends, Buybacks & Capital Allocation
OVID SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ovid Therapeutics Inc. (CIK: 0001636651)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 9, 2026 | 4 | xslF345X06/form4-04092026_050404.xml | View → |
| Apr 9, 2026 | 4 | xslF345X06/form4-04092026_050403.xml | View → |
| Apr 9, 2026 | 4 | xslF345X06/form4-04092026_050401.xml | View → |
| Mar 25, 2026 | 4 | xslF345X06/form4-03262026_010323.xml | View → |
| Mar 18, 2026 | 10-K | ovid-20251231.htm | View → |
❓ Frequently Asked Questions about OVID
What is the AI rating for OVID?
Ovid Therapeutics Inc. (OVID) has an AI rating of STRONG SELL with 76% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OVID's key strengths?
Claude: Revenue achieved 1181% YoY growth, indicating potential commercialization milestone or drug approval. Zero debt with $130.7M stockholders equity provides capital structure flexibility for raises.
What are the risks of investing in OVID?
Claude: Critical liquidity crisis: $13.2M cash against -$38.3M quarterly operating burn implies 4-month runway requiring imminent capital raise. Unsustainable profitability: -585% operating margin indicates operating expenses are nearly 6x revenue; commercialization traction insufficient to support cost structure.
What is OVID's revenue and growth?
Ovid Therapeutics Inc. reported revenue of $7.3M.
Does OVID pay dividends?
Ovid Therapeutics Inc. does not currently pay dividends.
Where can I find OVID SEC filings?
Official SEC filings for Ovid Therapeutics Inc. (CIK: 0001636651) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OVID's EPS?
Ovid Therapeutics Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OVID a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ovid Therapeutics Inc. has a STRONG SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OVID stock overvalued or undervalued?
Valuation metrics for OVID: ROE of -13.3% (sector avg: 15%), net margin of -240.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OVID stock in 2026?
Our dual AI analysis gives Ovid Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OVID's free cash flow?
Ovid Therapeutics Inc.'s operating cash flow is $-38.3M, with capital expenditures of $0.0. FCF margin is -528.6%.
How does OVID compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -240.1% (avg: 12%), ROE -13.3% (avg: 15%), current ratio 8.97 (avg: 2).